Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Purinergic receptor P2Y12 inhibitor

DRUG CLASS:

Purinergic receptor P2Y12 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D
CYSLTR2 L129Q	Uveal Melanoma	CYSLTR2 L129Q	Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D
GNAQ R183Q	Uveal Melanoma	GNAQ R183Q	Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D
GNAQ G48V	Uveal Melanoma	GNAQ G48V	Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D	MEK inhibitor + YM-254890 Sensitive: D – Preclinical MEK inhibitor + YM-254890 Sensitive : D